Practical Strategies for Optimizing IPF Care in Community Pulmonology Practice: A Clinician-Patient Conversation

This CME/CE activity is intended for pulmonology clinicians in community practices and in interstitial lung disease (ILD) centers who diagnose and manage patients with idiopathic pulmonary fibrosis (IPF).

Supported by educational grants from:

Genentech, Inc.

FACULTY

Gregory P. Cosgrove, MD, FCCP
Associate Professor
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, Colorado
Chief Medical Officer, Pulmonary Fibrosis Foundation
Chicago, Illinois

Kelly M. Newton, DO
Intensivist
TriStar Centennial Medical Center
Nashville, Tennessee

Glenda Rouland
Pulmonary Fibrosis Foundation Patient Ambassador
Birmingham, Alabama

PROGRAM OVERVIEW

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias. The disease is characterized by insidious onset and progressive decline in lung function due to fibrosis of the lung parenchyma. Although rare enough to be considered an orphan disease, IPF accounts for 15,000 to 40,000 deaths per year in the United States – and the incidence and mortality of IPF are increasing.

Despite advances in therapy, there is no cure for IPF and the prognosis of IPF is poor. Use of antifibrotic therapy may contribute to longer survival, but a substantial proportion of patients with IPF receive no pharmacologic therapy at all. Evidence and guidelines also support a multidisciplinary approach, demonstrating a need for
improved interprofessional communication, collaboration, and referral.

IPF places a significant burden on patients’ quality of life. Strong clinician-patient communication helps patients understand their disease, improves accuracy of diagnosis, and contributes to greater patient recognition of their role in IPF disease management. In this symposium, Individuals with IPF will join our expert faculty to share their personal journeys with the disease, illuminating gaps and successes in their care.

TARGET AUDIENCE

This CME/CE activity is intended for pulmonology clinicians in community practices and in interstitial lung disease (ILD) centers who diagnose and manage patients with idiopathic pulmonary fibrosis (IPF).

LEARNING OBJECTIVES

At the conclusion of this activity, participants should be better able to:

  • Identify the degree of impact of IPF on patients’ quality of life.
  • Describe the benefits of multidisciplinary care for IPF and the reasons for these benefits.
  • Engage a multidisciplinary care team to treat patients with IPF, by referral or collaboration.
  • Select appropriate pharmacologic and non-pharmacologic therapy and manage adverse events.
  • Demonstrate communication techniques for use with IPF patients that include effective disease-state and disease-management education, as well as support services available to them.

CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. For information about the certification of this activity, please contact Reese Walters, Postgraduate Institute for
Medicine at (720) 895-5357 or rwalters@pimed.com.

To Claim CME/CE Credit
If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14686. Upon registering and completing the activity evaluation, your certificate will be made available
immediately.

 

Jointly provided by Postgraduate Institute for Medicine and Global Academy for Medical Education. This symposium is not supported, endorsed or accredited by the American College of Chest Physicians.

© 2019 Global Academy for Medical Education, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission. Global Academy for Medical Education, LLC and Postgraduate Institute for Medicine will not assume responsibility for damages, loss, or
claims of any kind arising from or related to the information contained in this activity, including any claims related to the products, drugs, or services mentioned herein.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter
Gregory P. Cosgrove, MD

Reported Financial Relationship
Royalty: New Aera
Consulting: Boehringer Ingelheim
Contracted Research: Genentech, Boehringer Ingelheim, Global Blood Therapeutics

Name of Faculty or Presenter
Kelly M. Newton, DO

Reported Financial Relationship
Nothing to disclose

Name of Faculty or Presenter
Glenda Rouland

Reported Financial Relationship
Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager
Amanda Glazar, PhD

Reported Financial Relationship
Nothing to disclose

Name of Planner or Manager
Reese Walters

Reported Financial Relationship
Nothing to disclose

Name of Planner or Manager
Nicola Sirdevan

Reported Financial Relationship
Nothing to disclose

Name of Planner or Manager
Margaret McLaughlin

Reported Financial Relationship
Nothing to disclose

Name of Planner or Manager
Cate Abad

Reported Financial Relationship
Nothing to disclose

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine and Global Academy of Medical Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.